TCG Reports Active 2016 With Increased Interim Management and Consulting Work in the Rare Disease and Immuno-Oncology Fields

APRIL 27, 2017, RESEARCH TRIANGLE PARK (RTP), North Carolina, USA and HEIDELBERG, Germany — TCG (Technology Commercialization Group, LLC), an international life sciences firm headquartered in the RTP region of North Carolina with offices in Heidelberg has noticed a trend over the last years towards increased use of interim management. Why? In a business environment with shortening product life cycles and intense merger and acquisition activity, growing organizations often find themselves in need of competent, experienced management for a specific purpose over a relatively short period of time to manage their businesses to a value inflection point, often a financial exit or funding event.
Some examples of TCG interim management roles and consulting projects over the past year include the following:
  • Serving as Chief of US Commercial Operations for an Asian-based publicly traded biotech company preparing for a US market launch of a rare hematological disease drug.
  • Supported a North American oncology company in completing a Series C private fund raising.
  • Completed an out-licensing project for a publicly-traded US biotechnology company with an immuno-oncology drug.
  • Engaged as Chief Business Officer for an US-based private biotechnology company focused on infectious disease.
  • Evaluated and recommended the acquisition of a rare disease drug portfolio for a publicly traded mid-sized European pharmaceutical company.
  • Facilitated and negotiated the non-exclusive out-license of client’s gene therapy platform technology to a global big pharma company.
  • Engaged by a European specialty CRO to identify in-licensing opportunities.
  • Completed an out-licensing project for a private European biotechnology company with an acute coronary syndrome drug.
  • Engaged as Director of Business Development for a Regulatory CRO.
The firm enjoyed excellent growth throughout 2016, especially in its interim management services.  The company notes a particular interest from companies in the rare disease and immuno-oncology fields, two high growth areas in the pharmaceutical sector.